
  
    
      
        Background_NNP
        Opioid_NNP receptors_NNS belong_VBP to_TO the_DT large_JJ superfamily_RB of_IN G_NNP
        protein_NN coupled_VBN receptors_NNS [_NN 1_CD ]_NN ._. Three_CD major_JJ types_NNS of_IN
        opioid_NN receptors_NNS (_( μ_NN ,_, δ_NN and_CC κ_NN )_) have_VBP been_VBN cloned_VBN and_CC each_DT one_CD
        is_VBZ associated_VBN with_IN several_JJ physiological_JJ and_CC behavioural_NN
        roles_NNS ._. The_DT focus_NN of_IN the_DT present_JJ work_NN is_VBZ the_DT δ_NN opioid_NN
        receptor_NN ._. Delta_NN opioid_NN receptors_NNS play_VBP a_DT modulatory_NN role_NN in_IN
        analgesia_NN ,_, hibernation_NN ,_, autonomic_JJ nervous_JJ system_NN function_NN ,_,
        neuroendocrine_NN system_NN function_NN ,_, mood_NN driven_VBN behaviours_NNS and_CC
        olfaction_NN [_NN 2_CD ]_NN ._. Thus_RB ,_, understanding_VBG the_DT requirements_NNS for_IN
        activation_NN of_IN δ_NN opioid_NN receptors_NNS can_MD lead_VB to_TO identification_NN
        and_CC design_NN of_IN novel_NN drugs_NNS acting_VBG through_IN this_DT receptor_NN for_IN
        treatment_NN of_IN various_JJ physiological_JJ problems_NNS ._.
        While_IN designing_VBG drugs_NNS with_IN selectivity_NN to_TO a_DT single_JJ
        receptor_NN can_MD be_VB a_DT desirable_JJ approach_NN in_IN drug_NN design_NN ,_,
        another_DT approach_NN may_MD be_VB to_TO design_VB drugs_NNS that_WDT act_NN on_IN more_JJR
        than_IN one_CD receptor_NN ,_, but_CC with_IN differential_NN activity_NN on_IN each_DT
        receptor_NN ._. These_DT would_MD be_VB drugs_NNS that_WDT act_NN as_IN an_DT agonist_NN at_IN
        one_CD receptor_NN and_CC as_IN an_DT antagonist_NN or_CC partial_JJ agonist_NN at_IN
        another_DT receptor_NN type_NN ._. The_DT latter_JJ approach_NN would_MD be_VB useful_JJ
        in_IN situations_NNS where_WRB the_DT same_JJ receptor_NN type_NN that_IN mediates_NNS
        the_DT beneficial_JJ effect_NN of_IN the_DT drug_NN also_RB mediates_NNS the_DT
        untoward_NN effect_NN [_NN 3_CD ]_NN ._. In_IN this_DT case_NN interaction_NN with_IN
        another_DT receptor_NN type_NN could_MD reverse_VB the_DT unwanted_JJ effects_NNS
        associated_VBN with_IN the_DT activation_NN of_IN the_DT first_JJ receptor_NN ._.
        In_IN the_DT absence_NN of_IN comprehensive_JJ activation_NN data_NNS for_IN
        opioid_NN ligands_NNS at_IN δ_NN opioid_NN receptors_NNS ,_, we_PRP set_VBD out_IN to_TO
        characterize_VB a_DT set_NN of_IN fifteen_NN opioid_NN ligands_NNS for_IN their_PRP$
        activity_NN in_IN cells_NNS expressing_VBG only_RB δ_NN opioid_NN receptors_NNS ._. These_DT
        ligands_NNS were_VBD selected_VBN based_VBN on_IN our_PRP$ previous_JJ data_NNS showing_VBG
        that_IN they_PRP bound_VBN all_DT three_CD opioid_NN receptors_NNS [_NN 4_CD ]_NN ._. However_RB ,_,
        model_NN tissue_NN studies_NNS [_NN 5_CD ]_NN and_CC 
        in_IN vivo_NN studies_NNS [_NN 6_CD ]_NN had_VBD suggested_VBN
        that_IN these_DT ligands_NNS exhibited_VBN differential_NN activation_NN
        profiles_NNS at_IN the_DT three_CD opioid_NN receptors_NNS ._. Thus_RB the_DT present_JJ
        study_NN was_VBD designed_VBN ,_, (_( 1_LS )_) to_TO describe_VB the_DT activation_NN profiles_NNS
        of_IN a_DT set_NN of_IN opioid_NN ligands_NNS not_RB previously_RB defined_VBN at_IN an_DT
        isolated_VBN cell_NN system_NN expressing_VBG only_RB δ_NN opioid_NN receptors_NNS ,_,
        and_CC (_( 2_LS )_) to_TO compare_VB the_DT relative_JJ efficacies_NNS and_CC potencies_NNS of_IN
        these_DT ligands_NNS to_TO the_DT strongest_JJS ligand_NN in_IN the_DT set_VBN ,_,
        metazocine_NN ,_, to_TO the_DT common_JJ opioid_NN analgesic_JJ ,_, morphine_NN and_CC to_TO
        the_DT endogenous_JJ δ_NN opioid_NN ligand_NN ,_, met-enkephalin_JJ ._.
        In_IN this_DT study_NN ,_, the_DT activity_NN of_IN δ_NN opioid_NN receptor_NN was_VBD
        measured_VBN by_IN assessing_VBG the_DT levels_NNS of_IN inhibition_NN of_IN
        forskolin-stimulated_JJ cAMP_NN production_NN in_IN the_DT presence_NN of_IN
        various_JJ opioid_NN ligands_NNS ._. It_PRP has_VBZ been_VBN reported_VBN that_DT δ_NN opioid_NN
        receptors_NNS couple_NN more_RBR efficiently_RB to_TO adenylyl_NN cyclase_NN
        system_NN than_IN to_TO Ca_MD 2_CD +_NN channels_NNS [_NN 7_CD ]_NN ._. This_DT evidence_NN supports_VBZ
        the_DT use_NN of_IN cAMP_NN system_NN for_IN assessing_VBG the_DT activity_NN of_IN these_DT
        receptors_NNS ._. Moreover_RB ,_, cAMP_NN has_VBZ been_VBN implicated_VBN in_IN playing_VBG a_DT
        role_NN in_IN the_DT analgesic_JJ effects_NNS mediated_JJ through_IN δ_NN opioid_NN
        receptors_NNS [_NN 8_CD 9_CD ]_NN ._. Human_NNP embryonic_JJ kidney_NN cells_NNS stably_RB
        expressing_VBG mouse_NN δ_NN opioid_NN receptors_NNS were_VBD used_VBN to_TO
        characterize_VB the_DT activation_NN profiles_NNS of_IN opioid_NN ligands_NNS in_IN
        this_DT study_NN ._. The_DT results_NNS describe_VBP the_DT activity_NN of_IN a_DT set_NN of_IN
        ligands_NNS not_RB previously_RB characterized_VBN at_IN δ_NN opioid_NN receptors_NNS ._.
        The_DT results_NNS obtained_VBN from_IN this_DT study_NN will_MD serve_VB to_TO define_VB
        the_DT relative_JJ efficacies_NNS and_CC potencies_NNS of_IN a_DT set_NN of_IN opioid_NN
        ligands_NNS compared_VBN to_TO one_CD another_DT and_CC differentiate_VB between_IN
        the_DT full_JJ and_CC partial_JJ agonists_NNS at_IN δ_NN opioid_NN receptors_NNS ._.
      
      
        Results_NNS
        
          Receptor_NNP activation_NN
          All_DT ligands_NNS used_VBN (_( Table_NNP 1_LS )_) were_VBD non-peptide_JJ ligands_NNS
          selected_VBN for_IN lack_NN of_IN selectivity_NN for_IN different_JJ opioid_NN
          receptors_NNS ._. In_IN the_DT majority_NN of_IN cases_VBZ the_DT data_NNS were_VBD
          reproducible_JJ and_CC inter-experimental_JJ variability_NN was_VBD small_JJ
          (_( Figure_NN 1_LS )_) ._. Thus_RB the_DT data_NNS from_IN several_JJ experiments_NNS were_VBD
          normalized_JJ to_TO the_DT top_NN of_IN the_DT fitted_JJ curve_NN (_( no_DT ligand_NN ,_,
          forskolin_NN alone_RB )_) ,_, the_DT results_NNS of_IN several_JJ experiments_NNS
          pooled_VBN and_CC a_DT new_JJ fitted_JJ curve_NN constructed_VBN (_( Figure_NN 2_LS )_) ._. The_DT
          IC_NNP 
          50_CD values_NNS in_IN Table_NNP 1_CD are_VBP the_DT results_NNS of_IN
          the_DT pooled_VBN normalized_JJ data_NNS from_IN 3_CD or_CC more_JJR experiments_NNS
          carried_VBD out_IN in_IN duplicate_VB ._.
          Two_CD ligands_NNS ,_, nalbuphine_NN and_CC naltrexone_NN were_VBD
          categorized_VBN as_IN antagonists_NNS ._. All_DT other_JJ ligands_NNS studied_VBN
          showed_VBD a_DT robust_JJ inhibitory_NN effect_NN on_IN the_DT forskolin_NN
          stimulated_VBN cAMP_NN production_NN (_( Table_NNP 1_LS )_) ._. The_DT rank_NN order_NN of_IN
          efficacy_NN of_IN the_DT ligands_NNS tested_VBN was_VBD metazocine_NN =_SYM xorphanol_NN
          ≥_NN fentanyl_NN =_SYM SKF_NNP 10047_CD =_SYM etorphine_NN =_SYM hydromorphone_NN =_SYM
          butorphanol_NN =_SYM lofentanil_NN >_NN WIN_NNP 44_CD ,_, 441_CD =_SYM Nalbuphine_NNP =_SYM
          cyclazocine_NN ≥_NN met-enkephalin_JJ >_NN >_NN morphine_NN =_SYM
          dezocine_NN ._. Statistical_NNP analysis_NN showed_VBD that_IN most_JJS of_IN the_DT
          agonists_NNS tested_VBN had_VBD efficacies_NNS that_WDT were_VBD not_RB
          significantly_RB different_JJ from_IN that_DT of_IN the_DT endogenous_JJ
          ligand_NN met-enkephalin_JJ ._. The_DT only_JJ exceptions_NNS were_VBD the_DT
          highly_RB efficacious_JJ ligands_NNS fentanyl_NN (_( P_NN <_NN 0_CD ._. 05_CD )_) ,_,
          metazocine_NN (_( P_NN <_NN 0_CD ._. 001_CD )_) and_CC xorphanol_NN (_( p_NN <_NN
          0_CD ._. 001_CD )_) ._.
          The_DT potencies_NNS for_IN the_DT different_JJ ligands_NNS ranged_VBD from_IN
          0_CD ._. 2_CD -_: 2039_CD nM_NN ._. The_DT most_RBS potent_JJ ligands_NNS studied_VBN ,_, as_IN
          measured_VBN by_IN the_DT lowest_JJS IC_NNP 
          50_CD values_NNS (_( Table_NNP 1_LS )_) ,_, were_VBD etorphine_NN ,_,
          cyclazocine_NN ,_, lofentanil_NN ,_, and_CC xorphanol_NN with_IN IC_NNP 
          50_CD 's_POS of_IN less_JJR than_IN 10_CD nM_NN ._. The_DT other_JJ
          ligands_NNS ,_, met-enkephalin_JJ ,_, WIN_NNP 44_CD ,_, 441_CD ,_, hydromorphone_NN and_CC
          Butorphanol_NNP ,_, exhibited_VBN potencies_NNS of_IN 10_CD -_: 100_CD nM_NN ;_: metazocine_NN
          and_CC SKF_NNP 10047_CD ,_, 100_CD -_: 200_CD nM_NN ,_, and_CC nalbuphine_NN ,_, dezocine_NN and_CC
          morphine_NN ,_, 400_CD -_: 1000_CD nM_NN ._. The_DT least_JJS potent_JJ ligand_NN was_VBD
          fentanyl_NN with_IN an_DT IC_NNP 
          50_CD of_IN about_IN 2_CD μM_NN ._. The_DT rank_NN order_NN of_IN
          potency_NN of_IN these_DT ligands_NNS was_VBD ;_:
          etorphine_NN >_NN lofentanil_NN ≥_NN cyclazocine_NN =_SYM xorphanol_NN >_NN met-enkephalin_JJ >_NN
          Win_NNP 44_CD ,_, 441_CD =_SYM hydromorphone_NN ≥_NN butorphanol_NN >_NN metazocine_NN =_SYM SKF_NNP
          10047_CD >_NN dezocine_NN ≥_NN
          nalbuphine_NN >_NN morphine_NN >_NN fentanyl_NN ._.
          Figure_NN 2_CD depicts_VBZ dose-response_JJ curves_NNS of_IN a_DT
          representative_NN set_NN of_IN ligands_NNS ._. Etorphine_NNP and_CC lofentanil_NN
          are_VBP shown_VBN as_IN examples_NNS of_IN two_CD very_RB efficacious_JJ and_CC highly_RB
          potent_JJ ligands_NNS ._. SKF_NNP 10047_CD is_VBZ representative_NN of_IN a_DT very_RB
          efficacious_JJ ligand_NN with_IN intermediate_JJ potency_NN ._. Finally_RB ,_,
          fentanyl_NN is_VBZ shown_VBN as_IN an_DT example_NN of_IN a_DT ligand_NN with_IN very_RB low_JJ
          potency_NN ,_, which_WDT is_VBZ nevertheless_RB very_RB efficacious_JJ if_IN high_JJ
          enough_JJ concentrations_NNS are_VBP used_VBN ._.
        
        
          Receptor_NNP binding_JJ
          Human_NNP embryonic_JJ kidney_NN (_( HEK_NNP )_) cells_NNS were_VBD transfected_JJ to_TO
          express_VB mouse_NN δ_NN opioid_NN receptors_NNS ._. These_DT cells_NNS do_VBP not_RB
          express_VB any_DT endogenous_JJ δ_NN opioid_NN receptors_NNS ,_, as_IN they_PRP lack_VBP
          binding_VBG of_IN the_DT radioactive_JJ tracer_NN [_NN 3_CD H_NNP ]_NN -_: DPDPE_NNP (_( data_NNS not_RB
          shown_VBN )_) ,_, thus_RB they_PRP serve_VBP as_IN a_DT good_JJ system_NN for_IN the_DT
          expression_NN of_IN opioid_NN receptors_NNS ._. A_DT single_JJ clone_NN of_IN HEK_NNP
          cells_NNS ,_, stably_RB expressing_VBG 1925_CD ±_NN 425_CD fmole_NN /_NN mg_NN protein_NN δ_NN
          opioid_NN receptors_NNS ,_, was_VBD selected_VBN for_IN this_DT study_NN ._. The_DT K_NNP 
          d_SYM for_IN [_NN 3_CD H_NNP ]_NN -_: DPDPE_NNP in_IN these_DT cells_NNS was_VBD
          0_CD ._. 65_CD ±_NN 0_CD ._. 27_CD nM_NN ._. These_DT cells_NNS were_VBD used_VBN to_TO characterize_VB the_DT
          activity_NN of_IN fifteen_NN opioid_NN ligands_NNS in_IN inhibiting_VBG
          forskolin-stimulated_JJ cAMP_NN production_NN ._.
          Ligands_NNP that_WDT showed_VBD very_RB low_JJ potencies_NNS or_CC low_JJ enough_JJ
          efficacies_NNS to_TO be_VB tested_VBN for_IN antagonistic_JJ effect_NN were_VBD
          further_RBR characterized_VBN for_IN their_PRP$ binding_JJ affinities_NNS at_IN δ_NN
          opioid_NN receptors_NNS ._. All_DT ligands_NNS studied_VBN exhibited_VBN K_NNP 
          i_NNP values_NNS in_IN nanomolar_NN range_NN ._. The_DT rank_NN
          order_NN of_IN affinity_NN of_IN the_DT ligands_NNS was_VBD xorphanol_NN >_NN Win_NNP
          44_CD ,_, 441_CD >_NN nalorphine_NN >_NN morphine_NN ≥_NN nalbuphine_NN >_NN
          fentanyl_NN (_( Table_NNP 2_LS )_) ._. The_DT rank_NN order_NN of_IN affinity_NN agrees_VBZ
          with_IN the_DT rank_NN order_NN of_IN potency_NN of_IN these_DT ligands_NNS in_IN
          inhibiting_VBG forskolin-stimulated_JJ cAMP_NN production_NN ._.
        
      
      
        Discussion_NNP
        Ligands_NNP acting_VBG at_IN δ_NN receptors_NNS can_MD induce_VB antinociception_NN
        both_DT spinally_RB and_CC supraspinally_RB [_NN 10_CD 11_CD 12_CD ]_NN ,_, thus_RB
        identifying_VBG ligands_NNS that_WDT activate_VBP δ_NN opioid_NN receptors_NNS and_CC
        determining_VBG their_PRP$ physiochemical_JJ characteristics_NNS is_VBZ
        essential_JJ to_TO understanding_NN opioid_NN receptor_NN pharmacology_NN and_CC
        physiology_NN ._. There_EX is_VBZ evidence_NN suggesting_VBG that_DT δ_NN selective_JJ
        opioid_NN ligands_NNS do_VBP not_RB cause_VB changes_NNS in_IN respiratory_JJ
        parameters_NNS [_NN 13_CD ]_NN ._. Thus_RB ,_, suggesting_VBG that_IN designing_VBG
        specific_JJ ligands_NNS that_WDT act_NN at_IN δ_NN opioid_NN receptors_NNS may_MD be_VB
        useful_JJ in_IN formulating_VBG analgesics_NNS without_IN the_DT side_NN effect_NN of_IN
        ventilatory_NN depression_NN ._. Yet_RB ,_, some_DT selective_JJ δ_NN ligands_NNS have_VBP
        been_VBN shown_VBN to_TO be_VB ineffective_JJ antinociceptive_JJ agents_NNS when_WRB
        given_VBN systemically_RB [_NN 14_CD 15_CD 16_CD ]_NN ._. The_DT reason_NN for_IN this_DT
        ineffectiveness_NN is_VBZ not_RB clear_JJ ._. Still_RB ,_, other_JJ reports_NNS ,_, have_VBP
        suggested_VBN that_IN opioid_NN ligands_NNS with_IN agonistic_JJ effect_NN at_IN μ_NN
        opioid_NN receptors_NNS and_CC antagonistic_JJ effect_NN at_IN δ_NN opioid_NN
        receptors_NNS are_VBP potentially_RB useful_JJ analgesics_NNS [_NN 3_CD 17_CD 18_CD ]_NN ._.
        These_DT latter_JJ results_NNS advocate_VBP that_IN the_DT key_NN to_TO designing_VBG
        opioid_NN ligands_NNS with_IN optimal_NN analgesia_NN and_CC minimal_JJ side_NN
        effects_NNS may_MD be_VB in_IN the_DT design_NN of_IN ligands_NNS that_WDT act_NN on_IN more_JJR
        than_IN one_CD receptor_NN type_NN ,_, but_CC activate_VBP each_DT receptor_NN
        differently_RB ._. Thus_RB ,_, it_PRP is_VBZ useful_JJ to_TO identify_VB opioid_NN ligands_NNS
        with_IN differential_NN activation_NN profiles_NNS and_CC characterize_VB
        their_PRP$ physiological_JJ effects_NNS (_( analgesic_JJ and_CC unwanted_JJ
        effects_NNS )_) ._. Prior_RB to_TO the_DT design_NN of_IN any_DT novel_NN drugs_NNS based_VBN on_IN
        this_DT approach_NN ,_, it_PRP is_VBZ necessary_JJ to_TO clearly_RB understand_VB how_WRB
        the_DT known_VBN nonselective_JJ opioid_NN ligands_NNS act_VBP at_IN δ_NN opioid_NN
        receptors_NNS ._. Such_JJ information_NN can_MD not_RB only_RB help_VB explain_VB some_DT
        of_IN the_DT paradoxical_JJ behavioural_NN data_NNS of_IN these_DT ligands_NNS ,_, but_CC
        it_PRP can_MD also_RB explain_VB the_DT interaction_NN of_IN each_DT ligand_NN with_IN a_DT
        single_JJ receptor_NN involved_VBN in_IN modulation_NN of_IN the_DT pain_NN
        pathways_NNS ._. The_DT present_JJ data_NN serve_VBP to_TO define_VB the_DT mode_NN of_IN
        action_NN of_IN a_DT set_NN of_IN opioid_NN ligands_NNS at_IN δ_NN opioid_NN receptors_NNS and_CC
        will_MD help_VB explain_VB the_DT physiological_JJ effect_NN of_IN these_DT
        ligands_NNS ._. Moreover_RB ,_, since_IN δ_NN opioid_NN receptors_NNS have_VBP been_VBN
        reported_VBN to_TO exert_VB a_DT physiology_NN indicative_JJ of_IN regulatory_JJ
        effects_NNS on_IN hemodynamic_JJ balance_NN and_CC cardiac_JJ function_NN as_RB well_RB
        as_IN hibernation_NN ,_, a_DT better_JJR understanding_NN of_IN δ_NN receptor_NN
        pharmacology_NN can_MD lead_VB to_TO possible_JJ novel_NN uses_NNS of_IN δ_NN ligands_NNS
        independent_JJ of_IN analgesia_NN ._.
        The_DT present_JJ study_NN was_VBD designed_VBN as_IN one_CD of_IN the_DT steps_NNS in_IN
        defining_VBG the_DT detailed_VBN pharmacology_NN of_IN a_DT set_NN of_IN
        non-selective_JJ opioid_NN ligands_NNS and_CC aimed_VBN at_IN defining_VBG the_DT
        activation_NN profiles_NNS of_IN these_DT ligands_NNS at_IN a_DT well-defined_JJ
        system_NN expressing_VBG only_RB δ_NN opioid_NN receptors_NNS ._. The_DT use_NN of_IN such_JJ
        a_DT system_NN is_VBZ essential_JJ for_IN understanding_VBG the_DT mode_NN of_IN action_NN
        of_IN ligands_NNS at_IN a_DT specific_JJ receptor_NN ._. Such_JJ data_NNS can_MD then_RB be_VB
        used_VBN to_TO interpret_VB the_DT findings_NNS from_IN more_RBR complex_JJ settings_NNS ,_,
        such_JJ as_IN 
        in_IN vivo_NN studies_NNS ,_, where_WRB multiple_JJ
        opioid_NN receptor_NN types_NNS are_VBP expressed_VBN ._.
        The_DT data_NNS presented_VBN in_IN this_DT report_NN agree_VBP with_IN available_JJ
        published_VBN data_NNS ,_, thus_RB establishing_VBG that_IN the_DT methods_NNS used_VBN
        were_VBD valid_JJ and_CC could_MD be_VB successfully_RB used_VBN to_TO provide_VB useful_JJ
        data_NNS for_IN previously_RB uncharacterised_JJ ligands_NNS ._. For_IN example_NN ,_,
        as_IN reported_VBN ,_, etorphine_NN [_NN 19_CD ]_NN and_CC lofentanil_NN [_NN 20_CD ]_NN were_VBD
        shown_VBN to_TO be_VB highly_RB potent_JJ and_CC efficacious_JJ at_IN δ_NN opioid_NN
        receptors_NNS ._.
        Comparison_NNP of_IN the_DT efficacies_NNS of_IN the_DT set_NN of_IN agonists_NNS in_IN
        this_DT study_NN to_TO that_DT of_IN the_DT endogenous_JJ ligand_NN ,_,
        met-enkephalin_JJ ,_, showed_VBD that_IN all_DT were_VBD full_JJ agonists_NNS ._.
        Moreover_RB ,_, fentanyl_NN ,_, metazocine_NN and_CC xorphanol_NN could_MD be_VB
        considered_VBN "_'' super_JJ agonists_NNS "_'' at_IN delta_NN receptors_NNS based_VBN on_IN
        having_VBG efficacies_NNS significantly_RB greater_JJR than_IN
        met-enkephalin_JJ ._. This_DT observation_NN suggests_VBZ that_IN in_IN
        situations_NNS where_WRB the_DT endogenous_JJ ligand_NN is_VBZ present_JJ (_( such_JJ as_IN
        in_IN a_DT stressed_VBN animal_NN )_) ,_, it_PRP is_VBZ possible_JJ to_TO achieve_VB further_JJ
        activation_NN of_IN δ_NN opioid_NN receptors_NNS by_IN the_DT application_NN of_IN one_CD
        of_IN these_DT ligands_NNS ._. Moreover_RB ,_, the_DT efficacies_NNS of_IN the_DT above_JJ
        "_'' super_JJ agonists_NNS "_'' were_VBD comparable_JJ to_TO that_DT of_IN δ_NN selective_JJ
        ligands_NNS such_JJ as_IN SNC_NNP 80_CD and_CC BW_NNP 373_CD U_NNP 86_CD ._. Based_VBN on_IN previous_JJ
        reports_NNS ,_, maximum_NN inhibitory_NN effect_NN of_IN SNC-_NNP 80_CD in_IN transfected_JJ
        δ_NN opioid_NN receptors_NNS is_VBZ 71_CD ±_NN 5_CD %_NN [_NN 21_CD ]_NN and_CC 94_CD ±_NN 2_CD %_NN [_NN 22_CD ]_NN
        with_IN IC_NNP 
        50_CD values_NNS of_IN 15_CD and_CC 6_CD ._. 3_CD nM_NN respectively_RB ._.
        The_DT maximum_NN effect_NN of_IN BW_NNP 373_CD U_NNP 86_CD has_VBZ been_VBN reported_VBN to_TO be_VB 70_CD ±_NN
        9_CD %_NN with_IN IC_NNP 
        50_CD of_IN 0_CD ._. 9_CD nM_NN [_NN 21_CD ]_NN ._. Some_DT ligands_NNS that_WDT
        exhibited_VBN very_RB low_JJ potencies_NNS in_IN this_DT study_NN ,_, such_JJ as_IN
        fentanyl_NN or_CC metazocine_NN ,_, were_VBD amongst_IN the_DT most_RBS efficacious_JJ
        ligands_NNS tested_VBD suggesting_VBG that_IN these_DT ligands_NNS are_VBP capable_JJ of_IN
        maximally_RB activating_VBG δ_NN opioid_NN receptors_NNS ._. Thus_RB ,_, different_JJ
        concentrations_NNS of_IN these_DT ligands_NNS can_MD be_VB used_VBN to_TO achieve_VB
        various_JJ physiological_JJ effects_NNS based_VBN on_IN the_DT pharmacological_JJ
        properties_NNS of_IN these_DT ligands_NNS on_IN other_JJ opioid_NN receptors_NNS ._.
        Fentanyl_NNP is_VBZ a_DT synthetic_JJ opioid_NN ligand_NN belonging_VBG to_TO the_DT
        phenylpiperidine_NN family_NN of_IN ligands_NNS ._. Based_VBN on_IN receptor_NN
        binding_JJ assays_NNS ,_, fentanyl_NN has_VBZ an_DT affinity_NN for_IN μ_NN opioid_NN
        receptors_NNS ,_, that_WDT is_VBZ 100_CD -_: 1000_CD fold_VB higher_JJR than_IN that_DT for_IN δ_NN
        opioid_NN receptors_NNS [_NN 23_CD 24_CD ]_NN ._. However_RB ,_, no_DT published_VBN
        activation_NN data_NNS for_IN fentanyl_NN at_IN δ_NN opioid_NN receptors_NNS was_VBD
        available_JJ ._. 
        In_IN vivo_NN ,_, fentanyl_NN is_VBZ a_DT strong_JJ
        analgesic_JJ agent_NN in_IN pharmacological_JJ doses_NNS due_JJ to_TO its_PRP$
        interaction_NN with_IN μ_NN opioid_NN receptors_NNS [_NN 19_CD ]_NN ._. However_RB ,_, at_IN
        higher_JJR toxic_JJ doses_NNS it_PRP shows_VBZ general_JJ opioid_NN toxicity_NN
        symptoms_NNS in_IN addition_NN to_TO muscular_JJ rigidity_NN ,_, which_WDT are_VBP
        reversible_JJ by_IN naloxone_NN ._. Muscular_NNP rigidity_NN of_IN fentanyl_NN has_VBZ
        been_VBN suggested_VBN to_TO occur_VB via_IN several_JJ mechanism_NN involving_VBG
        glutamatergic_JJ pathways_NNS [_NN 25_CD ]_NN ,_, serotonergic_JJ system_NN [_NN 26_CD ]_NN
        as_RB well_RB as_IN noradrenergic_JJ system_NN [_NN 27_CD 28_CD ]_NN ._. One_CD other_JJ
        potential_JJ pathway_NN may_MD be_VB via_IN regulation_NN of_IN dopaminergic_JJ
        system_NN as_IN suggested_VBN before_IN [_NN 29_CD ]_NN possibly_RB via_IN δ_NN opioid_NN
        receptor_NN system_NN as_IN explained_VBN here_RB ._. It_PRP has_VBZ been_VBN reported_VBN
        that_DT stimulation_NN of_IN δ_NN opioid_NN receptors_NNS can_MD cause_VB inhibition_NN
        of_IN dopamine_NN release_NN in_IN striatal_NN pathways_NNS ,_, resulting_VBG in_IN
        muscular_JJ rigidity_NN [_NN 19_CD ]_NN ._. The_DT present_JJ report_NN shows_VBZ that_IN
        although_IN fentanyl_NN has_VBZ low_JJ affinity_NN and_CC low_JJ potency_NN at_IN δ_NN
        opioid_NN receptor_NN ,_, it_PRP is_VBZ highly_RB efficacious_JJ at_IN these_DT
        receptors_NNS ._. Thus_RB ,_, at_IN high_JJ fentanyl_NN concentrations_NNS δ_NN opioid_NN
        receptors_NNS can_MD also_RB be_VB fully_RB activated_VBN possibly_RB leading_VBG to_TO
        the_DT inhibition_NN of_IN dopamine_NN release_NN and_CC the_DT resultant_JJ muscle_NN
        rigidity_NN ._. So_IN the_DT data_NNS presented_VBN can_MD serve_VB to_TO describe_VB the_DT
        mechanism_NN of_IN action_NN and_CC physiological_JJ observations_NNS after_IN
        application_NN of_IN drugs_NNS 
        in_IN vivo_NN ._. Based_VBN on_IN the_DT present_JJ data_NN ,_,
        a_DT distinct_JJ effect_NN of_IN morphine_NN compared_VBN to_TO fentanyl_NN can_MD be_VB
        observed_VBN at_IN δ_NN opioid_NN receptors_NNS ._. While_IN fentanyl_NN is_VBZ a_DT full_JJ
        agonist_NN at_IN δ_NN opioid_NN receptors_NNS ,_, morphine_NN is_VBZ only_RB a_DT partial_JJ
        agonist_NN ._. Thus_RB ,_, although_IN both_DT these_DT drugs_NNS can_MD activate_VBP δ_NN
        opioid_NN receptors_NNS with_IN low_JJ potency_NN ,_, at_IN high_JJ concentrations_NNS
        morphine_NN cannot_NN stimulate_VB δ_NN receptor_NN as_RB effectively_RB as_IN
        fentanyl_NN ._. Thus_RB ,_, fentanyl_NN ,_, but_CC not_RB morphine_NN ,_, can_MD elicit_NN
        physiological_JJ changes_NNS that_WDT are_VBP mediated_JJ by_IN activation_NN of_IN δ_NN
        opioid_NN receptors_NNS ._.
        A_DT different_JJ scenario_NN holds_VBZ true_JJ for_IN the_DT two_CD ligands_NNS ,_,
        xorphanol_NN and_CC WIN_NNP 44_CD ,_, 441_CD ._. Both_DT these_DT ligands_NNS have_VBP high_JJ
        affinities_NNS and_CC potencies_NNS at_IN δ_NN opioid_NN receptors_NNS with_IN
        xorphanol_NN being_VBG very_RB efficacious_JJ at_IN δ_NN opioid_NN receptors_NNS ._. At_IN
        μ_NN opioid_NN receptors_NNS ,_, however_RB ,_, the_DT activation_NN profiles_NNS of_IN
        these_DT ligands_NNS are_VBP different_JJ ._. While_IN both_DT these_DT ligands_NNS bind_NN
        with_IN high_JJ affinities_NNS (_( less_JJR than_IN 1_CD nM_NN )_) to_TO μ_NN opioid_NN
        receptors_NNS ,_, WIN_NNP 44_CD ,_, 441_CD acts_NNS as_IN an_DT antagonist_NN at_IN μ_NN opioid_NN
        receptors_NNS and_CC xorphanol_NN is_VBZ a_DT very_RB weak_JJ agonist_NN at_IN μ_NN opioid_NN
        receptor_NN (_( Gharagozlou_NNP et_CC al_NN ._. unpublished_JJ results_NNS )_) ._. Thus_RB
        these_DT ligands_NNS can_MD be_VB useful_JJ in_IN clinical_JJ applications_NNS where_WRB
        activation_NN of_IN δ_NN opioid_NN receptors_NNS needs_VBZ to_TO be_VB combined_VBN with_IN
        a_DT weak_JJ action_NN or_CC an_DT antagonistic_JJ action_NN at_IN μ_NN opioid_NN
        receptors_NNS ._. Such_JJ an_DT application_NN can_MD be_VB very_RB important_JJ due_NN to_TO
        the_DT unique_JJ physiology_NN of_IN δ_NN opioid_NN receptors_NNS ._. Studies_NNS such_JJ
        as_IN presented_VBN here_RB can_MD serve_VB to_TO provide_VB the_DT data_NNS necessary_JJ
        for_IN application_NN of_IN opioid_NN ligands_NNS in_IN such_JJ unique_JJ settings_NNS ._.
        Moreover_RB ,_, until_IN now_RB the_DT activity_NN of_IN xorphanol_NN at_IN δ_NN opioid_NN
        receptors_NNS had_VBD not_RB been_VBN described_VBN ._. This_DT ligand_NN had_VBD been_VBN
        described_VBN as_IN a_DT mixed_JJ agonist-antagonist_JJ opioid_NN ligand_NN [_NN 30_CD
        31_CD ]_NN with_IN agonistic_JJ activity_NN at_IN κ_NN opioid_NN receptors_NNS [_NN 32_CD ]_NN ._.
        Overall_RB very_RB little_JJ work_NN has_VBZ been_VBN done_VBN on_IN xorphanol_NN and_CC
        little_JJ is_VBZ known_VBN about_IN it_PRP except_IN that_IN it_PRP is_VBZ an_DT orally_RB active_JJ
        analgesic_JJ with_IN limited_JJ physical_JJ dependence_NN liability_NN [_NN 30_CD ]_NN
        ._. Thus_RB the_DT present_JJ report_NN describing_VBG its_PRP$ activity_NN at_IN δ_NN
        opioid_NN receptors_NNS provides_VBZ useful_JJ data_NNS on_IN this_DT ligand_NN ._.
        Nalorphine_NNP ,_, has_VBZ been_VBN previously_RB categorized_VBN as_RB a_DT "_'' mixed_JJ
        agonist_NN /_NN antagonist_NN "_'' ligand_NN [_NN 6_CD ]_NN ._. These_DT are_VBP ligands_NNS that_WDT
        are_VBP believed_VBN to_TO act_VB as_IN an_DT agonist_NN at_IN κ_NN and_CC as_IN an_DT antagonist_NN
        at_IN μ_NN opioid_NN receptors_NNS ._. No_DT published_VBN 
        in_IN vitro_NN data_NNS was_VBD available_JJ for_IN the_DT
        activation_NN profile_NN of_IN this_DT ligand_NN at_IN δ_NN opioid_NN receptors_NNS ._. In_IN
        this_DT study_NN nalorphine_NN was_VBD shown_VBN to_TO be_VB an_DT antagonist_NN at_IN δ_NN
        opioid_NN receptor_NN with_IN a_DT moderate_JJ binding_JJ affinity_NN ._. Such_JJ a_DT
        moderate_JJ affinity_NN makes_VBZ it_PRP possible_JJ for_IN nalorphine_NN to_TO
        antagonize_VB the_DT effect_NN of_IN other_JJ ligands_NNS or_CC the_DT endogenous_JJ
        ligand_NN (_( like_IN met-enkephalin_JJ )_) at_IN δ_NN opioid_NN receptors_NNS while_IN
        possibly_RB acting_VBG as_IN an_DT agonist_NN at_IN other_JJ opioid_NN receptors_NNS ._.
        Based_VBN on_IN the_DT regulatory_JJ role_NN of_IN δ_NN opioid_NN receptors_NNS such_JJ
        applications_NNS may_MD be_VB numerous_JJ ._. Data_NNP similar_JJ to_TO the_DT one_CD
        presented_VBN in_IN this_DT report_NN ,_, will_MD open_VB the_DT door_NN for_IN novel_NN
        applications_NNS of_IN these_DT ligands_NNS in_IN the_DT treatment_NN of_IN various_JJ
        ailments_NNS ._.
      
      
        Conclusions_NNP
        The_DT present_JJ study_NN was_VBD designed_VBN to_TO characterize_VB the_DT
        activation_NN profiles_NNS of_IN a_DT set_NN of_IN opioid_NN ligands_NNS in_IN cells_NNS
        expressing_VBG only_RB δ_NN opioid_NN receptors_NNS ._. These_DT ligands_NNS had_VBD not_RB
        been_VBN previously_RB characterized_VBN at_IN δ_NN opioid_NN receptors_NNS ._. The_DT
        data_NNS produced_VBN from_IN this_DT study_NN can_MD be_VB used_VBN to_TO achieve_VB
        several_JJ goals_NNS ._. (_( 1_LS )_) These_DT data_NNS can_MD lead_VB to_TO elucidation_NN of_IN
        the_DT complete_JJ activation_NN profiles_NNS of_IN these_DT ligands_NNS ,_, leading_VBG
        to_TO clarification_NN of_IN the_DT mechanisms_NNS involved_VBN in_IN
        physiological_JJ effects_NNS of_IN these_DT ligands_NNS at_IN δ_NN opioid_NN
        receptor_NN ._. (_( 2_LS )_) These_DT data_NNS can_MD be_VB used_VBN as_IN a_DT basis_NN for_IN novel_NN
        use_NN of_IN existing_VBG opioid_NN ligands_NNS based_VBN on_IN their_PRP$ pharmacology_NN
        at_IN δ_NN opioid_NN receptors_NNS ._. (_( 3_LS )_) These_DT 
        in_IN vitro_NN data_NNS can_MD be_VB utilized_JJ to_TO
        define_VB the_DT physiochemical_JJ features_NNS of_IN the_DT ligands_NNS defining_VBG
        agonism_NN and_CC antagonism_NN at_IN δ_NN opioid_NN receptors_NNS ,_, leading_VBG to_TO
        design_VB and_CC discovery_NN of_IN novel_NN opioid_NN analgesics_NNS ._. (_( 4_LS )_) In_IN
        combination_NN with_IN 
        in_IN vivo_NN data_NNS characterizing_VBG analgesic_JJ
        and_CC unwanted_JJ effects_NNS of_IN these_DT ligands_NNS ,_, the_DT 
        in_IN vitro_NN data_NNS can_MD be_VB used_VBN to_TO identify_VB
        the_DT activation_NN profile_NN of_IN the_DT ideal_JJ opioid_NN analgesic_JJ that_WDT
        has_VBZ minimal_JJ side_NN effects_NNS ._. Such_JJ information_NN ,_, combined_VBN with_IN
        the_DT knowledge_NN on_IN the_DT physiochemical_JJ characteristics_NNS of_IN the_DT
        agonists_NNS and_CC antagonists_NNS at_IN each_DT receptor_NN ,_, will_MD lead_VB to_TO the_DT
        design_NN of_IN novel_NN opioid_NN analgesics_NNS with_IN minimal_JJ side_NN
        effects_NNS ._.
      
      
        Methods_NNP
        
          Cell_NNP culture_NN
          Human_NNP Embryonic_NNP Kidney_NNP (_( HEK_NNP )_) 293_CD cells_NNS were_VBD maintained_VBN
          in_IN D-MEM_NNP /_NN F-_NNP 12_CD (_( Dulbecco_NNP 's_POS Modified_NNP Eagle_NNP 's_POS Medium_NNP :_:
          Nutrient_NNP Mixture_NNP F-_NNP 12_CD 1_CD :_: 1_CD mixture_NN )_) ,_, supplemented_JJ with_IN 10_CD %_NN
          (_( v_NN /_NN v_NN )_) fetal_JJ calf_NN serum_NN (_( FCS_NNP )_) ,_, 200_CD μg_NN /_NN ml_NN G-_NNP 418_CD (_( Geneticin_NNP
          ®_NN )_) in_IN a_DT humidified_JJ incubator_NN with_IN 5_CD %_NN CO_NNP 
          2_CD and_CC 95_CD %_NN air_NN ,_, at_IN 37_CD °_NN C_NNP ._. The_DT incubation_NN
          medium_NN was_VBD changed_VBN every_DT 3_CD -_: 4_CD days_NNS ._. Once_RB a_DT week_NN ,_, cells_NNS
          were_VBD re-plated_JJ at_IN 20_CD %_NN density_NN into_IN 75_CD -_: cm_NN 2_CD tissue_NN culture_NN
          flasks_NNS ._.
        
        
          Transformation_NNP of_IN δ_NN opioid_NN receptors_NNS and_CC isolation_NN
          of_IN stable_JJ cells_NNS
          Stably_NNP transfected_JJ HEK_NNP cells_NNS were_VBD developed_VBN as_IN
          described_VBN previously_RB [_NN 33_CD ]_NN ._. HEK_NNP 293_CD cells_NNS were_VBD
          transfected_JJ with_IN the_DT cDNA_NN for_IN mouse_NN δ_NN opioid_NN receptor_NN in_IN
          the_DT pCI-neo_JJ ®_NN vector_NN ._. The_DT mouse_NN δ_NN cDNA_NN was_VBD obtained_VBN in_IN the_DT
          vector_NN pCMV_NN (_( a_DT generous_JJ gift_NN from_IN Dr_NNP ._. Graham_NNP Bell_NNP ,_,
          University_NNP of_IN Chicago_NNP )_) ._. The_DT 1_CD ._. 2_CD kb_NN coding_VBG sequence_NN of_IN the_DT
          receptor_NN was_VBD subcloned_JJ into_IN pCI-neo_JJ ®_NN mammalian_JJ expression_NN
          vector_NN (_( Promega_NNP ,_, Madison_NNP ,_, WI_NNP )_) using_VBG the_DT restriction_NN sites_NNS
          EcoRI_NNP and_CC Sal_NNP I_PRP ._. HEK_NNP 293_CD cell_NN were_VBD transfected_JJ with_IN the_DT
          vector_NN using_VBG the_DT lipofectin_NN ®_NN reagent_NN (_( Life_NNP Technologies_NNPS ,_,
          Rockville_NNP ,_, MD_NNP )_) ._. Stable_NNP clones_NNS were_VBD selected_VBN using_VBG 400_CD
          μg_NN /_NN ml_NN Geneticin_NNP ®_NN ._. Single_NNP clone_NN were_VBD picked_VBN and_CC tested_VBN
          for_IN expression_NN of_IN δ_NN opioid_NN receptor_NN by_IN binding_JJ assay_NN ._. One_CD
          clone_NN expressing_VBG 1925_CD ±_NN 425_CD fmoles_NNS /_NN mg_NN protein_NN ,_, as_IN
          assessed_VBN by_IN [_NN 3_CD H_NNP ]_NN -_: DPDPE_NNP binding_JJ ,_, was_VBD propagated_JJ for_IN use_NN
          in_IN this_DT study_NN ._.
        
        
          Binding_NNP assays_NNS
          Saturation_NNP binding_JJ assays_NNS were_VBD carried_VBN out_IN for_IN [_NN
          3_CD H_NNP ]_NN -_: DPDPE_NNP in_IN HEK_NNP cells_NNS as_IN described_VBN previously_RB [_NN 34_CD ]_NN ._.
          Crude_JJ cell_NN homogenate_NN (_( 20_CD -_: 25_CD μg_NN of_IN per_IN assay_NN tube_NN )_) was_VBD
          used_VBN and_CC incubation_NN was_VBD in_IN 50_CD mM_NN Tris_NNP HCl_NNP ,_, pH_NN 7_CD ._. 4_CD at_IN room_NN
          temperature_NN for_IN 2_CD hours_NNS ._. The_DT assay_NN was_VBD terminated_VBN by_IN
          rapid_JJ filtration_NN through_IN Whatman_NNP GF_NNP /_NN B_NNP filters_NNS using_VBG a_DT
          FilterMate_NNP cell_NN harvester_NN (_( Packard_NNP Instruments_NNP )_) followed_VBN
          by_IN three_CD washes_NNS ,_, 4_CD ml_NN each_DT ,_, with_IN ice_NN cold_JJ buffer_NN ._.
          Radioactivity_NNP retained_VBD on_IN the_DT filters_NNS was_VBD measured_VBN using_VBG
          Microscint_NNP 0_CD in_IN a_DT TopCount_NNP liquid_JJ scintillation_NN counter_NN
          (_( Packard_NNP Instruments_NNP )_) ._. Competition_NN binding_JJ assays_NNS were_VBD
          carried_VBN out_IN in_IN crude_NN membrane_NN homogenate_NN of_IN HEK-δ_NNP cells_NNS ._.
          Binding_NNP was_VBD carried_VBN out_IN in_IN 250_CD μl_NN volume_NN of_IN 50_CD mM_NN Tris_NNP
          HCl_NNP buffer_NN ,_, pH_NN 7_CD ._. 4_CD in_IN the_DT presence_NN of_IN 0_CD ._. 5_CD -_: 1_CD nM_NN [_NN
          3_CD H_NNP ]_NN -_: DPDPE_NNP and_CC increasing_VBG concentrations_NNS (_( 24_CD -_: 32_CD different_JJ
          concentrations_NNS )_) of_IN unlabeled_JJ ligand_NN ._. Incubation_NNP and_CC
          binding_JJ were_VBD as_IN described_VBN above_IN ._. Binding_NNP data_NNS were_VBD
          analyzed_VBN using_VBG the_DT Affinity_NNP Analysis_NNP Software_NNP as_IN
          described_VBN before_IN [_NN 34_CD 35_CD ]_NN ._. For_IN preparation_NN of_IN crude_NN
          membrane_NN homogenate_NN ,_, confluent_NN cultures_NNS of_IN HEK-δ_NNP cells_NNS
          were_VBD harvested_VBN using_VBG phosphate_NN buffered_JJ saline_NN ._. Following_VBG
          centrifugation_NN at_IN 700_CD ×_NN g_SYM ,_, the_DT cell_NN pellet_NN was_VBD resuspended_JJ
          in_IN ice-cold_JJ 50_CD mM_NN Tris_NNP HCl_NNP buffer_NN pH_NN 7_CD ._. 4_CD at_IN about_IN 10_CD
          7_CD cell_NN /_NN ml_NN ,_, and_CC homogenized_JJ using_VBG a_DT polytron_NN at_IN setting_VBG 6_CD
          for_IN 10_CD seconds_NNS ._. The_DT cell_NN homogenate_NN was_VBD stored_VBN in_IN
          aliquots_NNS at_IN -_: 86_CD °_NN C_NNP until_IN use_NN ._. Protein_NNP content_NN of_IN the_DT cell_NN
          homogenate_NN was_VBD determined_VBN using_VBG Bio-_NNP Rad_NNP protein_NN assay_NN
          reagent_NN (_( Bio-_NNP Rad_NNP ,_, Hercules_NNP ,_, CA_NNP )_) ._.
        
        
          Whole_JJ cell_NN adenylyl_NN cyclase_NN assays_NNS
          Inhibition_NNP of_IN Forskolin_NNP stimulated_VBN cyclic_JJ AMP_NNP (_( cAMP_NN )_)
          production_NN by_IN exposure_NN to_TO increasing_VBG concentrations_NNS of_IN
          agonists_NNS were_VBD evaluated_VBN in_IN intact_JJ cells_NNS ._. Exponentially_NNP
          growing_VBG HEK-δ_NNP cells_NNS were_VBD harvested_VBN and_CC resuspended_JJ in_IN
          serum_NN free_JJ DMEM_NNP /_NN F_NN 12_CD medium_NN ._. Cells_NNP were_VBD plated_JJ in_IN 96_CD well_RB
          microtiter_NN plates_NNS at_IN 5_CD ×_NN 10_CD 4_CD cells_NNS /_NN well_RB in_IN 100_CD μl_NN volume_NN ._.
          To_TO each_DT well_RB ,_, phosphodiesterase_NN inhibitor_NN
          3_CD -_: isobutyl-_NN 1_CD -_: methylxanthine_NN (_( IBMX_NNP )_) was_VBD added_VBN to_TO a_DT final_JJ
          concentration_NN of_IN 100_CD μM_NN ,_, followed_VBN by_IN addition_NN of_IN agonists_NNS
          at_IN different_JJ concentrations_NNS and_CC incubation_NN at_IN 37_CD °_NN C_NNP ._.
          Following_VBG 15_CD minutes_NNS incubation_NN ,_, forskolin_NN was_VBD added_VBN to_TO
          each_DT well_RB to_TO a_DT final_JJ concentration_NN of_IN 5_CD μM_NN followed_VBN by_IN
          another_DT incubation_NN for_IN 15_CD min_NN at_IN 37_CD °_NN C_NNP ._. The_DT final_JJ reaction_NN
          volume_NN was_VBD 200_CD μl_NN ._. The_DT reaction_NN was_VBD terminated_VBN by_IN
          aspiration_NN of_IN the_DT medium_NN and_CC addition_NN of_IN 200_CD μl_NN lysis_NNS
          buffer_NN from_IN the_DT Biotrak_NNP ™_NN cAMP_NN Enzyme_NNP Immunoassay_NNP kit_NN from_IN
          Amersham_NNP Pharmacia_NNP Biotech_NNP (_( Buckinghamshire_NNP ,_, England_NNP )_) ._.
          The_DT rest_NN of_IN the_DT assay_NN followed_VBD the_DT protocol_NN provided_VBN with_IN
          the_DT kit_NN ._. Actual_JJ amount_NN of_IN cAMP_NN was_VBD determined_VBN for_IN each_DT
          sample_NN in_IN comparison_NN to_TO a_DT standard_JJ curve_NN of_IN known_VBN amounts_NNS
          of_IN cAMP_NN provided_VBN in_IN the_DT cAMP_NN kit_NN ,_, as_IN described_VBN in_IN the_DT kit_NN
          protocol_NN ._.
        
        
          Agonism_NNP
          Agonistic_NNP activity_NN of_IN opioid_NN ligands_NNS was_VBD assessed_VBN by_IN
          measuring_VBG the_DT inhibitory_NN effect_NN of_IN the_DT ligands_NNS on_IN
          forskolin-stimulated_JJ cAMP_NN accumulation_NN ._. Data_NNS from_IN each_DT
          experiment_NN were_VBD normalized_JJ to_TO the_DT top_NN of_IN the_DT curve_NN (_( no_DT
          ligand_NN ,_, 100_CD %_NN )_) ,_, expressed_VBD as_IN percent_NN inhibition_NN of_IN
          forskolin-stimulated_JJ cAMP_NN accumulation_NN and_CC were_VBD fit_VBN to_TO a_DT
          sigmoidal_NN function_NN by_IN using_VBG one_CD site_NN competition_NN function_NN
          as_IN described_VBN below_IN ._. The_DT efficacy_NN of_IN each_DT ligand_NN was_VBD
          defined_VBN as_IN percent_NN inhibition_NN of_IN forskolin_NN stimulated_VBN
          cAMP_NN production_NN compared_VBN to_TO no_DT ligand_NN levels_NNS (_( 0_CD %_NN
          inhibition_NN ,_, 100_CD %_NN cAMP_NN production_NN )_) ._.
        
        
          Antagonism_NNP
          Compounds_NNP with_IN very_RB little_JJ 
          in_IN vitro_NN agonistic_JJ activity_NN
          (_( <_NN 20_CD %_NN inhibition_NN of_IN cAMP_NN production_NN )_) for_IN which_WDT the_DT
          dose_NN response_NN curves_NNS could_MD not_RB be_VB fitted_JJ ,_, were_VBD tested_VBN for_IN
          antagonism_NN ._. Antagonists_NNP were_VBD identified_VBN as_IN ligands_NNS that_WDT
          were_VBD able_JJ to_TO repeatedly_RB block_VB the_DT inhibitory_NN effect_NN of_IN 1_CD
          nM_NN etorphine_NN on_IN forskolin_NN stimulated_VBN cAMP_NN production_NN ._. In_IN
          these_DT assays_NNS ,_, antagonist_NN was_VBD added_VBN to_TO the_DT cells_NNS along_IN
          with_IN IBMX_NNP ._. After_IN 15_CD minutes_NNS of_IN incubation_NN ,_, the_DT agonist_NN
          was_VBD added_VBN and_CC the_DT cells_NNS were_VBD incubated_JJ with_IN both_DT ligands_NNS
          for_IN an_DT additional_JJ 10_CD minutes_NNS ._. After_IN addition_NN of_IN
          forskolin_NN ,_, the_DT cells_NNS were_VBD incubated_JJ for_IN 15_CD additional_JJ
          minutes_NNS ._. The_DT rest_NN of_IN the_DT assay_NN was_VBD as_IN described_VBN
          above_IN ._.
        
        
          Curve_NNP fitting_JJ
          The_DT analysis_NN of_IN ligand_NN activity_NN was_VBD performed_VBN using_VBG
          PRISM_NNP software_NN (_( GraphPad_NNP Software_NNP ,_, Inc_NNP ._. San_NNP Diego_NNP ,_, CA_NNP )_) ._. A_DT
          computer-generated_JJ "_'' best_JJS fit_VB "_'' of_IN non-linear_JJ regression_NN
          data_NNS was_VBD used_VBN to_TO provide_VB estimate_NN of_IN IC_NNP 
          50_CD ._. Dose_NNP response_NN data_NNS generated_VBN by_IN
          cAMP_NN enzyme_NN immunoassay_NN (_( EIA_NNP )_) system_NN were_VBD fitted_JJ with_IN the_DT
          one_CD site_NN competition_NN function_NN ._.
        
        
          Data_NNP processing_NN
          Data_NNS from_IN each_DT dose_NN response_NN curve_NN were_VBD normalized_JJ to_TO
          the_DT top_NN of_IN the_DT respective_JJ curve_NN ._. The_DT normalized_JJ data_NN from_IN
          multiple_JJ dose_NN response_NN curves_NNS were_VBD combined_VBN and_CC a_DT new_JJ
          dose_NN response_NN curve_NN was_VBD fitted_JJ to_TO the_DT combined_VBN data_NN and_CC
          maximal_NN inhibition_NN was_VBD determined_VBN for_IN the_DT combined_VBN data_NN ._.
          IC_NNP 
          50_CD values_NNS presented_VBN are_VBP the_DT mean_JJ ±_NN SEM_NNP
          of_IN IC_NNP 
          50_CD values_NNS from_IN 2_CD -_: 3_CD independent_JJ
          experiments_NNS ._.
        
        
          Drugs_NNS used_VBN
          Forskolin_NNP ,_, fentanyl_NN ,_, IBMX_NNP ,_, hydromorphone_NN ,_, and_CC
          naltrexone_NN were_VBD obtained_VBN from_IN Sigma-_NNP Aldrich_NNP (_( St_NNP ._. Louis_NNP ,_,
          MO_NNP )_) ,_, nalbuphine_NN and_CC met-enkephalin_JJ were_VBD obtained_VBN from_IN RBI_NNP
          (_( Natik_NNP ,_, MA_NNP )_) ,_, cyclazocine_NN ,_, etorphine_NN ,_, metazocine_NN ,_,
          morphine_NN ,_, nalorphine_NN ,_, and_CC SKF_NNP 10047_CD were_VBD obtained_VBN from_IN
          National_NNP Institute_NNP of_IN Drug_NNP Abuse_NNP (_( Bethesda_NNP ,_, MD_NNP )_) ,_,
          lofentanil_NN was_VBD obtained_VBN from_IN Janssen_NNP Pharmaceutical_NNP Inc_NNP ._.
          (_( Titusville_NNP ,_, NJ_NNP )_) ,_, Dezocine_NNP was_VBD obtained_VBN from_IN Wyeth_NNP
          Laboratories_NNPS (_( Philadelphia_NNP ,_, PA_NNP )_) ,_, Win_NNP 444_CD ,_, 441_CD was_VBD obtained_VBN
          from_IN Sterling_NNP Winthrop_NNP Pharmaceutical_NNP and_CC Xorphanol_NNP was_VBD
          obtained_VBN from_IN Miles_NNP Inc_NNP ._. Pharmaceutical_NNP Division_NNP (_( West_NNP
          Haven_NNP ,_, CT_NNP )_) ._. All_DT tissue_NN culture_NN reagents_NNS were_VBD purchased_VBN
          from_IN Life_NNP Technologies_NNPS (_( Rockville_NNP ,_, MD_NNP )_) ._. DPDPE_NNP was_VBD
          obtained_VBN from_IN Peninsula_NNP Laboratories_NNPS (_( San_NNP Carlos_NNP ,_, CA_NNP )_) ,_,
          and_CC [_NN 3_CD H_NNP ]_NN -_: DPDPE_NNP was_VBD from_IN Multiple_NNP Peptide_NNP Systems_NNPS (_( San_NNP
          Diego_NNP ,_, CA_NNP )_) ._. All_DT other_JJ reagents_NNS were_VBD of_IN analytical_JJ grade_NN
          from_IN standard_JJ commercial_JJ sources_NNS ._.
          All_DT ligands_NNS used_VBN were_VBD prepared_VBN as_IN 10_CD mM_NN stock_NN
          solutions_NNS in_IN water_NN except_IN WIN_NNP 44_CD ,_, 441_CD ,_, which_WDT was_VBD 5_CD mM_NN ._. All_DT
          ligands_NNS were_VBD dissolved_VBN in_IN distilled_VBN water_NN except_IN
          cyclazocine_NN ,_, dezocine_NN ,_, etorphine_NN ,_, which_WDT were_VBD dissolved_VBN in_IN
          100_CD %_NN ethanol_NN ._. For_IN the_DT drugs_NNS dissolved_VBN in_IN ethanol_NN ,_, the_DT
          final_JJ concentration_NN of_IN ethanol_NN was_VBD <_NN 0_CD ._. 01_CD %_NN which_WDT had_VBD no_DT
          affect_NN on_IN the_DT assays_NNS performed_VBN ._.
        
        
          Statistical_NNP analysis_NN
          Maximal_NNP inhibitory_NN effect_NN of_IN each_DT ligand_NN was_VBD compared_VBN
          to_TO the_DT levels_NNS of_IN maximal_NN inhibition_NN by_IN met-enkephalin_JJ ,_,
          metazocine_NN and_CC morphine_NN using_VBG ANOVA_NNP analysis_NN with_IN
          Dunnett_NNP 's_POS multiple_JJ comparison_NN as_IN post_NN test_NN using_VBG PRISM_NNP
          software_NN (_( GraphPad_NNP Software_NNP ,_, Inc_NNP ._. San_NNP Diego_NNP ,_, CA_NNP )_) ._.
          Significant_JJ difference_NN between_IN the_DT inhibitory_NN effects_NNS of_IN
          two_CD ligands_NNS was_VBD determined_VBN whenever_WRB p_NN <_NN 0_CD ._. 05_CD ._.
        
      
      
        Authors_NNP '_'' contributions_NNS
        PG_NNP carried_VBD out_RP the_DT bulk_NN of_IN the_DT cAMP_NN assays_NNS ,_, data_NNS and_CC
        statistical_JJ analysis_NN and_CC drafted_VBD the_DT manuscript_NN ._. HD_NNP carried_VBD
        out_RP some_DT of_IN the_DT initial_JJ experiments_NNS and_CC data_NNS analysis_NN work_NN ._.
        JDC_NNP provided_VBD intellectual_JJ input_NN and_CC critical_JJ interpretation_NN
        of_IN the_DT data_NNS ._. JL_NNP conceived_VBD of_IN the_DT study_NN ,_, participated_VBD in_IN its_PRP$
        design_NN and_CC coordination_NN ,_, carried_VBD out_RP the_DT binding_JJ assays_NNS and_CC
        finalized_VBD the_DT manuscript_NN for_IN publication_NN ._.
      
    
  
